Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- IBCP +6.5%, PHG +5%, HAS +4.9%, EDU +4%, HAL +1.8%, PDS +1.6%, ITW +1.6%, OPB +1%, SYT +0.7%, TRST +0.6%
M&A news:
- BCR +19.3% (C.R. Bard (BCR) to be acquired by Becton Dickinson and Co (BDX) for $317.00 per share)
Select financial related names showing strength post French elections:
- DB +10.2%, BBVA +7.4%, ING +7%, SAN +6.4%, BCS +5.7%, CS+4.9%, RBS +2.8%, C +2.4%, HSBC +2.4%, MS +2.2%, BAC +2.1%,JPM +2%, GS +2%
Select EU stocks trading higher with regional indices higher by 2-5%:
- ORAN +6%, SNY +5.1%, MT +4.6%, ERIC +4.3%, NOK +4.2%, STM+4%, SAP +3.6%, ALV +3.5%, ASML +3.2%, UN +2.9%, RACE+2.9%, MTL +2.9%, BBL +2.9%, CCE +2.6%, BHP +2.2%, RIO+2.2%, ABB +2%, NVO +1.8%, GLPG +1.4%
Select oil/gas related names showing strength:
- AEG +5.2%, TOT +4.8%, RDS.A +2.2%, BP +1.8%, WLL +1.7%
Other news:
- OPTT +44.8% (co's PB3 PowerBuoy was deployed off the coast of Kozu-shima Island in Japan as part of its first lease agreement with Mitsui Engineering and Shipbuilding)
- AMDA +18.4% (granted marketing clearance for its Valeo interbody fusion devices in Australia)
- DRRX +15.7% (clinical data on DUR-928 were presented )
- HTGM +5.4% (enters into a research collaboration agreement with Instituto Valenciano de Oncología)
- PRTK +3% (presents data from its Phase 3 study of omadacycline)
- NVS +1.5% (reports new data confirming benefit of Gilenya on 4 key measures of disease activity in relapsing MS)
Analyst comments:
- MLCO +4.1% (upgraded to Buy from Hold at Union Gaming)
- AKS +3.1% (upgraded to Outperform from Neutral at Macquarie)
- XLNX +2.4% (upgraded to Outperform from Neutral at Credit Suisse)
- NUE +2.3% (upgraded to Neutral from Underperform at Macquarie)
- X +2% (upgraded to Neutral from Underperform at Macquarie)
- AMZN +1.1% (target raised to $1250 at Wedbush)